{
  "metformin": {
    "molecule": "Metformin",
    "atc_class": "A10BA02",
    "regions": {
      "US": {
        "market_size_usd_mn": 850.5,
        "cagr_5y_percent": 3.2,
        "volume_trend": "stable",
        "competitors": [
          {"company": "Teva", "share_percent": 18},
          {"company": "Mylan", "share_percent": 15},
          {"company": "Lupin", "share_percent": 10}
        ]
      },
      "EU5": {
        "market_size_usd_mn": 420.0,
        "cagr_5y_percent": 2.1,
        "volume_trend": "declining",
        "competitors": [
          {"company": "Sandoz", "share_percent": 20}
        ]
      }
    },
    "therapy_dynamics": [
      "Shift from monotherapy to fixed-dose combinations",
      "Increased use in prediabetes and insulin resistance"
    ],
    "sales_trends": [
      {"year": 2020, "revenue_usd_mn": 760},
      {"year": 2021, "revenue_usd_mn": 790},
      {"year": 2022, "revenue_usd_mn": 820},
      {"year": 2023, "revenue_usd_mn": 845},
      {"year": 2024, "revenue_usd_mn": 850}
    ],
    "volume_shifts": [
      {"channel": "Retail", "delta_percent": -2.0},
      {"channel": "Hospital", "delta_percent": 3.5},
      {"channel": "Mail Order", "delta_percent": 5.0}
    ],
    "therapy_competition": [
      {"therapy_area": "T2D", "key_players": ["Teva", "Mylan", "Lupin"], "price_pressure": "High"},
      {"therapy_area": "NAFLD (off-label)", "key_players": ["Smaller specialty"], "price_pressure": "Low"},
      {"therapy_area": "Prediabetes", "key_players": ["Generic mix"], "price_pressure": "Medium"}
    ]
  },

  "montelukast": {
    "...": "..."
  }
}
